These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38070405)

  • 1. Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: A study of 42 patients.
    Caraballo RH; Reyes G; Chacón S; Fortini PS
    Epilepsy Behav; 2024 Jan; 150():109561. PubMed ID: 38070405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brivaracetam for the treatment of refractory epilepsy in patients with prior exposure to levetiracetam: A retrospective outcome analysis.
    Snoeren A; Majoie MHJM; Fasen KCFM; Ijff DM
    Seizure; 2022 Mar; 96():102-107. PubMed ID: 35184005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRIVEST: A 'real-world' observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam.
    Naddell S; Manuel M; Cavill R; White P; Sieradzan K
    Epilepsy Behav; 2023 Jan; 138():108985. PubMed ID: 36442261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
    Green SF; Hare N; Kassam M; Rugg-Gunn F; Koepp MJ; Sander JW; Rajakulendran S
    Epilepsy Behav; 2022 Oct; 135():108868. PubMed ID: 35985166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
    Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up.
    Strzelczyk A; Zaveta C; von Podewils F; Möddel G; Langenbruch L; Kovac S; Mann C; Willems LM; Schulz J; Fiedler B; Kurlemann G; Schubert-Bast S; Rosenow F; Beuchat I
    Epilepsia; 2021 Dec; 62(12):2994-3004. PubMed ID: 34608628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation.
    Adewusi J; Burness C; Ellawela S; Emsley H; Hughes R; Lawthom C; Maguire M; McLean B; Mohanraj R; Oto M; Singhal S; Reuber M
    Epilepsy Behav; 2020 May; 106():106967. PubMed ID: 32179501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents.
    Schubert-Bast S; Willems LM; Kurlemann G; Knake S; Müller-Schlüter K; Rosenow F; Strzelczyk A
    Epilepsy Behav; 2018 Dec; 89():89-93. PubMed ID: 30390435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence.
    Russo A; Pruccoli J; Cesaroni CA; Belotti LMB; Zenesini C; Bonanni P; Boni A; Cesaroni E; Coppola G; Cordelli DM; Danieli A; Mancardi MM; Marchese F; Matricardi S; Messana T; Nocera GM; Operto FF; Pellino G; Reina F; Vanadia F; Verrotti A; Striano P
    Seizure; 2022 Nov; 102():120-124. PubMed ID: 36223675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
    Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
    Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).
    Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Chiesa V; Dainese F; De Maria G; Didato G; Falcicchio G; Fanella M; Ferlazzo E; Fisco G; Gangitano M; Giallonardo AT; Giorgi FS; La Neve A; Mecarelli O; Montalenti E; Piazza F; Pulitano P; Quarato PP; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
    CNS Drugs; 2021 Dec; 35(12):1289-1301. PubMed ID: 34476770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
    Hirsch M; Hintz M; Specht A; Schulze-Bonhage A
    Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study.
    Liguori C; Manfredi N; Renna R; Izzi F; Pagliuca M; Pagliuca F; Mercuri NB; Fabio P
    Epileptic Disord; 2020 Jun; 22(3):309-316. PubMed ID: 32540833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
    Steinhoff BJ; Klein P; Klitgaard H; Laloyaux C; Moseley BD; Ricchetti-Masterson K; Rosenow F; Sirven JI; Smith B; Stern JM; Toledo M; Zipfel PA; Villanueva V
    Epilepsy Behav; 2021 May; 118():107939. PubMed ID: 33839453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive brivaracetam - A prospective audit of outcomes from an epilepsy clinic.
    Stephen L; Brodie MJ
    Epilepsy Behav; 2021 Mar; 116():107746. PubMed ID: 33517200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis.
    Moseley BD; Dimova S; Elmoufti S; Laloyaux C; Asadi-Pooya AA
    Epilepsy Res; 2021 Oct; 176():106694. PubMed ID: 34218211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Brivaracetam in children with epilepsy.
    Ferragut Ferretjans F; Soto Insuga V; Bernardino Cuesta B; Cantarín Extremera V; Duat Rodriguez A; Legido MJ; González Alguacil E; Furones García M; Gutiérrez Solana L; Moreno Cantero T; Ruiz Falcó ML; García Peñas JJ
    Epilepsy Res; 2021 Nov; 177():106757. PubMed ID: 34530305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open-label, single-arm study.
    Pressler R; Boylan G; Dempsey E; Klotz KA; Krauwinkel W; Will E; Morita D; Floricel F; Elshoff JP; van den Anker J
    Epilepsia Open; 2024 Apr; 9(2):522-533. PubMed ID: 38049197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.
    Arnold S; Laloyaux C; Schulz AL; Elmoufti S; Yates S; Fakhoury T
    Epilepsy Res; 2020 Oct; 166():106404. PubMed ID: 32731118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.